FLT3 and acute myeloid leukemia: Quizartinib, another selective FLT3 inhibitor, was evaluated in a phase III trial (QuANTUM-First) to assess its efficacy compared to chemotherapy in newly diagnosed FLT3-ITD AML patients [25].